AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of -0.290–0.240 for the period, compared to the consensus earnings per share estimate of -0.260. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $337.6 million.

AngioDynamics Stock Up 2.6%

Shares of NASDAQ ANGO opened at $11.52 on Friday. AngioDynamics has a 12 month low of $9.39 and a 12 month high of $16.29. The business has a fifty day simple moving average of $15.32 and a 200-day simple moving average of $13.10. The company has a market cap of $484.46 million, a price-to-earnings ratio of -14.77 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.43%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts expect that AngioDynamics will post -0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ANGO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. HC Wainwright upped their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of AngioDynamics in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.00% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.